dm+d
Unassigned
New Medicines
Psoriasis - moderate to severe plaque
Information
New molecular entity
VBL Therapeutics
VBL Therapeutics
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Feb 15: VBL Therapeutics announces that its PII studies evaluating VB-201 in patients with psoriasis and ulcerative colitis did not meet their primary endpoints. VBL does not plan to continue development of VB-201 in these indications [3].
Category
first-in-class, orally-available, specific innate immunity disease-modifying medicine from a series of proprietary oxidized phospholipid analogues
20 March 2012Psoriasis affects approx 2% of Europeans, with 90% of these having plaque psoriasis. Peaks in late teens and again in middle age. [2]
Psoriasis - moderate to severe plaque
Oral